Estudios y artículos sobrela diabetes y el Aceite de Coco, los Ácidos Grasos de cadena media (MCFA) y otros productos asociados:
In vivo antinociceptive and anti-inflammatory activities of dried and fermented processed virgin coconut oil. Med Princ Pract. 2011;20(3):231-6. Epub 2011 Mar 29.
Coconut oil is associated with a beneficial lipid profile in pre-menopausal women in the Philippines. Asia Pac J Clin Nutr. 2011;20(2):190-5.
Effect of saturated fatty acid-rich dietary vegetable oils on lipid profile, antioxidant enzymes and glucose tolerance in diabetic rats. Indian J Pharmacol. 2010 Jun;42(3):142-5.
Anti-inflammatory, analgesic, and antipyretic activities of virgin coconut oil. Pharm Biol. 2010 Feb;48(2):151-7.
Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol Res. 2010 Mar;61(3):208-12. Epub 2009 Nov 30.
Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity. Lipids. 2009 Jul;44(7):593-601. Epub 2009 May 13.
Medium-chain fatty acids ameliorate insulin resistance caused by high-fat diets in rats. Diabetes Metab Res Rev. 2009 Feb;25(2):185-94. Diabetes Metab Res Rev.
Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes.2009 May;58(5):1237-44. Epub 2009 Feb 17.
Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects. Metabolism. 2007 Jul;56(7):985-91.
Lower weight gain and higher expression and blood levels of adiponectin in rats fed medium-chain TAG compared with long-chain TAG. Lipids. 2006 Feb;41(2):207-12.
Results of use of metformin and replacement of starch with saturated fat in diets of patients with type 2 diabetes. Endocr Pract. 2002 May-Jun;8(3):177-83.
Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects. Diabetes. 1992 May;41(5):641-7.
Insulinotropic potency of lauric acid: a metabolic rationale for medium chain fatty acids (MCF) in TPN formulation. (FCM) en la formulación de la NPT. J Surg Res. 1992 Apr;52(4):328-33.
Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse. Biochem Med 1985;33:104-109.
Eucaloric substitution of medium chain triglycerides for dietary long chain fatty acids in Sustitución acquired total lipodystrophy: effects on hyperlipoproteinemia and endogenous insulin resistance. J Clin Endocrinol Metab. 1983 Sep;57(3):517-23.
Medium-chain fats in dietetic treatment of some disorders of the digestive tract. Pol Tyg Lek. 1972 Jul 31;27(31):1207-10.
Experimental Diabetes and Diet. Science. 1947 May 23;105(2734):548-9.
Comentarios recientes